Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly & Co. Director J. Erik Fyrwald acquired 10.026 shares of common stock through a deferred compensation plan.

Summary

• J. Erik Fyrwald, a Director at Eli Lilly & Co. (LLY), acquired 10.026 shares of common stock.
• The transaction occurred on March 16, 2026, at a price of $989.12 per share.
• These shares were acquired as stock units under the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Mr. Fyrwald's separation from service.
• Following this transaction, Mr. Fyrwald beneficially owns 75,258.776 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's decision to defer cash compensation into company stock demonstrates confidence in Eli Lilly's long-term prospects and aligns their interests with shareholders.

Positives

• A Director is increasing their beneficial ownership in the company, which can signal confidence in the company's future performance.
• The acquisition is part of a deferred compensation plan, aligning the director's long-term interests with shareholders.

Future Outlook

The filing indicates that the acquired stock units will be settled in shares of common stock following the reporting person's separation from service, aligning future compensation with long-term company performance.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly through deferred compensation plans, are common practice in the pharmaceutical industry, aligning executive and director incentives with long-term shareholder value. This type of transaction is a routine part of corporate governance for many large-cap companies like Eli Lilly.

Comparison to Industry Standards

• This transaction is consistent with common corporate governance practices among large pharmaceutical companies, where directors often elect to receive equity as part of their compensation to align their interests with shareholders.
• For example, similar deferred stock unit plans are utilized by directors at companies such as Pfizer (PFE) and Johnson & Johnson (JNJ), where equity compensation is a standard component of director remuneration.

Stakeholder Impact

• Shareholders: Potentially positive, as director stock ownership aligns interests.
• Management/Directors: The director is increasing their equity stake, linking their personal wealth more closely to the company's performance.

Next Steps

• Settlement of stock units into common stock upon the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled acquisition of a relatively small number of shares by a director as part of a deferred compensation plan. While it signals insider confidence, it does not present new fundamental information that would warrant a change in investment thesis. Investors should continue to hold based on broader company fundamentals rather than this specific transaction.

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Stock Acquisition, Deferred Compensation, J. Erik Fyrwald, Stock Units, Rule 10b5-1